Eligible trials included those evaluating IL-17 or IL-23 inhibitors for PsO and documented PASI scores. Interleukin-17 (IL-17) inhibitors demonstrated faster psoriasis (PsO) clearance than Interleukin ...

Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Although TNF inhibitors remain the first choice biologic ...

Authors of an observational cohort study published in the Journal of the European Academy of Dermatology and Venereology investigated the efficacy of interleukin-17 inhibitors (IL-17i) for the ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE registry ...

Eli Lilly has taken a high-stakes gamble on oral IL-17 inhibitors, betting $2.4 billion upfront that acquiring Dice Therapeutics will expand its autoimmune arsenal. The deal, which has already been ...

This retrospective cohort study analysed the effectiveness and survival of patients with psoriasis undergoing therapeutic biologic dose spacing of secukinumab or brodalumab. The analysis included 80 ...

DUBLIN – Affibody AB is getting $10 million up front and up to $215.5 million in regulatory and sales milestones from a licensing deal with Inmagene Biopharmaceuticals Co. Ltd., in which the latter ...

Acelyrin, a biopharma firm, acquired licenses for izokibep, a potential treatment for inflammatory disorders, and completed a successful IPO, raising $621 million. Acelyrin's shares surged 35% after ...